Vericel Corporation (VCEL) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $34.49, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Matricel; Negative momentum.
Vericel Corporation markets three FDA-approved therapies in the US: MACI (knee cartilage repair), Epicel (severe burn skin replacement), and NexoBrid (eschar removal for burn patients), targeting orthopedic surgeons and burn care specialists. Revenue comes from specialty... Read more
Hold if already holding. Not a fresh buy at $34.49, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Matricel; Negative momentum. Chart setup: RSI 55 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Vericel Corporation
Latest news
- VCEL (Vericel Corporation) reports 13.1 percent Q4 2025 EPS beat, shares fall 6.23 percent in today’s trading. - Earning — Newser positive
- Insider Sell: Paul Wotton Sells 10,000 Shares of Vericel Corp (V - GuruFocus — GuruFocus negative
- Vericel Corporation (VCEL) reports Q1 loss, beats revenue estimates - MSN — MSN positive
- Vericel Corporation (VCEL) reports Q1 loss, beats revenue estimates - msn.com — msn.com positive
- Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T20:21:22Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierMatricel10-K Item 1: 'The Matricel Supply Agreement provides that Matricel will supply the ACI-Maix membranes exclusively to us during the term of the agreement'
- MEDIUMSupplierMediWound10-K Item 1A: 'The commercial success of NexoBrid in the U.S. is dependent, in part, on MediWound’s ability to timely manufacture and supply sufficient quantities of NexoBrid to meet customer demand'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $34.49, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Matricel; Negative momentum. Chart setup: RSI 55 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $48.22 (+39.8%), stop $32.08 (−7.5%), A.R:R 3.4:1. Score 6.0/10, moderate confidence.
Take-profit target: $48.22 (+39.8% upside). Target $48.22 (+39.8%), stop $32.08 (−7.5%), A.R:R 3.4:1. Stop-loss: $32.08.
Concentration risk — Supplier: Matricel; Negative momentum; Below 200-MA, MA slope -2.1%/30d (confirmed downtrend).
Vericel Corporation trades at a P/E of 81.1 (forward 40.9). TrendMatrix value score: 5.7/10. Verdict: Hold.
14 analysts cover VCEL with a consensus score of 4.2/5. Average price target: $55.
What does Vericel Corporation do?Vericel Corporation markets three FDA-approved therapies in the US: MACI (knee cartilage repair), Epicel (severe burn...
Vericel Corporation markets three FDA-approved therapies in the US: MACI (knee cartilage repair), Epicel (severe burn skin replacement), and NexoBrid (eschar removal for burn patients), targeting orthopedic surgeons and burn care specialists. Revenue comes from specialty pharmacy sales (MACI) and hospital sales (Epicel/NexoBrid); net income was $16.5M in 2025. Matricel GmbH is the sole collagen membrane supplier for MACI manufacturing.